Please assess the completion status of the following clinical trial:

Trial Title: RESTART C0168Z05 Rheumatoid Arthritis Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have rheumatoid arthritis~* Patients must have greater than or equal to 6 tender joints and greater than or equal to 6 swollen joints~* Patients must have inadequate disease response to etanercept or adalimumab~* Patients must have received etanercept or adalimumab in combination with methotrexate for a minimum of at least 3 months prior to the screening visit. The last dose of etanercept must have been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion.~Exclusion Criteria:~* Patients who have a history of latent or active TB~* Have inflammatory disease other than rheumatoid arthritis~* Have had a chronic or recurrent infectious disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: OTHER): Infliximab3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response

Based on this trial design, predict the completion outcome and termination type (if applicable).